Canadian Justices Balk At 'Promise Doctrine' In Drug IP Row
The Supreme Court of Canada on Friday found that an AstraZeneca patent asserted against Apotex Inc. was not invalid, dealing a blow to the country's controversial "promise doctrine," which requires inventions...To view the full article, register now.
Already a subscriber? Click here to view full article